Navigation Links
Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
Date:9/25/2008

Total Value of the Commitment to the CGI is an Estimated $210 Million

Crofelemer, Once Approved for Children, Could Aid in Treating Diarrhoel Diseases That Kill An Estimated 2.5 million Children Each Year

NEW YORK, Sept. 25 /PRNewswire-USNewswire/ -- Napo Pharmaceuticals, Inc., ("Napo") of South San Francisco, California, whose novel anti-diarrheal compound crofelemer is currently in development, has agreed to provide access to crofelemer for pediatric populations in disaster situations and resource-constrained geographies, pending successful registration of crofelemer as an FDA approved product (and any local registration requirements). The commitment is being made as part of the Clinton Global Initiative.

Crofelemer is a late-stage gastro-intestinal agent which treats watery diarrhea, and is sustainably harvested from Amazonian rain forests and manufactured in India in accordance with FDA Good Manufacturing Practices. According to the World Health Organization, up-to approximately 2.5 million children die from diarrhea each year. Crofelemer in clinical trials has demonstrated the ability to decrease the loss of fluid from the intestines of infected patients regardless of the infectious agent causing the watery diarrhoea. Crofelemer has recently demonstrated efficacy in clinical trials in acute infectious diarrhea of multiple etiologies including severely ill cholera patients. CRO-PED is a pediatric formulation of crofelemer currently under development.

Persistent acute diarrhea in children can have significant and devastating impairment of growth, fitness, school performance and cognitive function. Additionally, chronic diarrhea is a common problem for people living with HIV/AIDS, often leading to death in children. The Crofelemer Access Program ("CAP") announced September 19, 2008, aims to provide CRO-PED to millions of children in geographies hard-hit by diseases such as HIV/AIDS and cholera.

As part of the CAP, Napo a
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
2. DFB Sells Coria Labs to Valeant Pharmaceuticals
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
5. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
6. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
7. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
8. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
9. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
11. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... San Diego, CA, and Bellingham, WA (PRWEB) August ... nanoscience and optical engineering, visions for next-generation wearable ... Light 2015 among numerous highlights at this year’s ... in the San Diego, California, Convention Center. More ... suppliers last week attended conferences, courses, an exhibition, ...
(Date:8/26/2014)... and REHOVOT, Israel , August 26, ... 3D printing specialist, Replica 3DM, supports NHS hospitals with surgery ...   - Performing surgery on 3D ... times; improves patient recovery and provides an effective aid for ... Ltd. (Nasdaq: SSYS ), a global leader ...
(Date:8/26/2014)... CA (PRWEB) August 26, 2014 The ... USD 8,020.1 million by 2020, according to a new ... personalized medicine and theranostics, and the subsequent introduction of ... factors driving market growth over the next six years. ... chronic diseases such as cancer, coupled with disease triggering ...
(Date:8/26/2014)... Aug. 26, 2014  Guardant Health, a healthcare ... oncology diagnostic products, has been recognized today by ... Technology Pioneer . As an innovator in non-invasive, ... companies across a wide variety of industries and ... Guardant360 ® , Guardant Health,s first commercially ...
Breaking Biology Technology:Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2
... , Newly Launched Donor Network Alliance Achieves Company & Industry ... June 24 Through a unique and effective collaboration of ... Network Alliance (DNA) - the industry,s first ever web-based collective ... largest egg donation resources in the country with more than ...
... Release Highlights, - Melogliptin continues to demonstrate potential to be ... incidence of, hypoglycemia and neutral effect on body ... end 2009, - IND approved by USFDA, ... Indian company to have a truly global innovative drug for the ...
... PROMOTIONAL SYSTEMS, INC. (Pink Sheets: VGPR) today announced through ... planning to construct a manufacturing facility in the State ... , , According to a recent Forbes Magazine ... abundance of biomass in Georgia,s Bioenergy Corridor ranks third ...
Cached Biology Technology:First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S. 2Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials 2Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 2Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 3
(Date:8/26/2014)... feeding patients through a tube, in an intensive care ... practice of a certain amount of feeding per hour ... to a volume-based system, which calls for a certain ... a system was found to be effective in ICU ... the American Society for Parenteral and Enteral Nutrition,s (A.S.P.E.N.) ...
(Date:8/26/2014)... Unregulated trash burning around the globe is pumping far ... records. A new study led by the National Center ... of the world,s garbage is burned in such fires, ... health and climate change. , The new study provides ... pollutants such as particulates, carbon monoxide, and mercury that ...
(Date:8/26/2014)... an increased risk of autism among children of ... reflect the known increased risk associated with severe ... online publication in Molecular Psychiatry , investigators ... while a diagnosis of autism spectrum disorder was ... antidepressants during pregnancy than in those with no ...
Breaking Biology News(10 mins):Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3
... New Rochelle, NY, October 30, 2009Sponsored by ... by BioConferences International, Inc., GREENBioPharma is the first ... and technologies available for sustainable life science organizations. ... and methods, but also on the economic rationales ...
... the fight against the deadly Hendra virus following the development ... lives of people who become infected with the virus. ... demonstrated that administering human monoclonal antibodies after exposure to Nipah ... from challenge in a disease model. According to CSIRO,s ...
... around the world are becoming more like the highly diverse ... has led UOG professors Thomas Marler and Seyda Turk-Smith to ... of teaching to a group of learners with a range ... and learning more about how my psychology research can be ...
Cached Biology News:Breakthrough in fight against Hendra virus 2Multicultural education focus of new UOG publication 2
... a commonly used technique for studying protein ... electrophoresed on SDS-PAGE and transferred to a ... they are probed with specific antibodies. Unlike ... of Southern and Northern blots, it has ...
... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 amino ... human DNA fragmentation factor (DFF). The sequence of this ... P - K - S - V - K - ... S - P - R - K(18). This ...
Biology Products: